Patients who developed biochemical recurrence had a higher PSA at diagnosis, more advanced pT stages, a higher rate of pN1 stage disease, a higher rate of R1 or Rx resection, and a higher rate of ...

New recommendations prioritise multiparametric MRI, safer transperineal biopsy, and earlier escalation for high-risk prostate-specific antigen relapse.

The prostate inflammation score of biopsy cores is associated with biochemical recurrence risk and might improve prediction of prostate cancer aggressiveness. The degree of inflammation in prostate ...

OBJECTIVES: To identify retrospectively through chart analysis the biochemical recurrence frequency of localized prostate cancer at diagnosis of patients submitted to surgery or radiotherapy; to ...

SAN ANTONIO -- More than 2 years after treatment, no patient with high-risk prostate cancer had a confirmed biochemical recurrence after receiving postoperative apalutamide (Erleada) and androgen ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...

The postsurgical combination of androgen deprivation therapy and Erleada has shown promising results in prostate cancer. Postsurgical treatment with androgen deprivation therapy and Erleada ...

New research suggests that men who take multivitamins after being diagnosed with prostate cancer may have a lower risk of cancer recurrence. In the overall study group, current multivitamin users ...